Key Insights

Highlights

Success Rate

90% trial completion (above average)

Published Results

18 trials with published results (23%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

6.5%

5 terminated out of 77 trials

Success Rate

90.4%

+3.9% vs benchmark

Late-Stage Pipeline

19%

15 trials in Phase 3/4

Results Transparency

38%

18 of 47 completed with results

Key Signals

18 with results90% success

Data Visualizations

Phase Distribution

46Total
Not Applicable (8)
Early P 1 (3)
P 1 (8)
P 2 (12)
P 3 (12)
P 4 (3)

Trial Status

Completed47
Recruiting14
Unknown6
Terminated5
Not Yet Recruiting3
Active Not Recruiting2

Trial Success Rate

90.4%

Benchmark: 86.5%

Based on 47 completed trials

Clinical Trials (77)

Showing 20 of 20 trials
NCT07081997Phase 3RecruitingPrimary

A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

NCT07540286Phase 2RecruitingPrimary

An Cohort Study on the Safety and Efficacy of XH-02 in Treating Hypoparathyroidism

NCT07264634RecruitingPrimary

A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)

NCT07530705Phase 1RecruitingPrimary

Efficacy and Safety of Subcutaneous Injection of XH-02 in the Treatment of Adult Hypoparathyroidism

NCT07197450Early Phase 1RecruitingPrimary

Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism

NCT06465108Phase 2CompletedPrimary

Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism

NCT00743782Phase 2CompletedPrimary

Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism

NCT07345494RecruitingPrimary

A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

NCT06961071Phase 1RecruitingPrimary

Parathyroid Allotransplant for Treatment of Hypoparathyroidism

NCT05965167Phase 1CompletedPrimary

Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo

NCT07395388Not ApplicableCompleted

Intraoperative Methylene Blue Spray for the Identification and Preservation of Vital Structures in Thyroidectomy

NCT04701203Phase 3CompletedPrimary

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism

NCT07299838CompletedPrimary

Palopegteriparatide in Chronic Hypoparathyroidism

NCT05556629CompletedPrimary

A Survey to Assess Participants' and Physicians' Knowledge, Attitudes and Behavior When Using NATPARA

NCT05387070Phase 3CompletedPrimary

PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

NCT05793853RecruitingPrimary

Hypoparathyroidism Natural History Study

NCT02924532CompletedPrimary

Postoperative Dose of Parathyroid Hormone as a Marker for the Occurrence of Hypoparathyroidism After Total Thyroidectomy

NCT07083557Recruiting

Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)

NCT06531941Phase 2Active Not RecruitingPrimary

Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism

NCT01922440Active Not RecruitingPrimary

A Registry for Participants With Chronic Hypoparathyroidism

Scroll to load more

Research Network

Activity Timeline